Ranibizumab (Lucentis®, Byooviz™, and Cimerli™) Injection

Ranibizumab (Lucentis, Byooviz, Cimerli) is covered for the listed FDA‑approved indications (neovascular AMD, RVO‑related macular edema, DME, DR, mCNV) and certain compendial off‑label neovascular ophthalmic uses, with coverage limited to those diagnoses. Key requirements: documented diagnosis, administration by or under an ophthalmologist, adherence to indication‑specific intravitreal dosing (0.5 mg monthly for AMD/RVO; 0.3 mg monthly for DME/DR; 0.5 mg monthly for up to 3 months for mCNV), and approvals up to 12 months.

"Myopic choroidal neovascularization (mCNV)"

Sign up to see full coverage criteria, indications, and limitations.